You can accelerate drug development in alloimmunization & HDFN

(hemolytic disease of the fetus and newborn (HDFN), also known as erythroblastosis fetalis)

Your experience with alloimmunization & HDFN is important and can help researchers advance treatments for your community.

By joining AllStripes, you can contribute your de-identified medical records to multiple research efforts for alloimmunization & HDFN without leaving home. We do the work to collect your information, and you’ll receive all your records in your secure account, at no cost.

0/30 research participants

Help this community hit the research goal by sharing with your network!

Who’s involved?

Allo Hope Foundation

Allo Hope Foundation

How sharing your journey powers progress

  • Jumpstart new research for your rare disease

    Your (or your loved one’s) medical records contain clues that can lead to new treatments.

  • Determine important symptoms to target

    AllStripes researchers learn from patient records what would truly improve quality of life.

  • Speed up development of treatments

    Using cutting-edge tech we analyze your community’s data to improve trial design and chances of success.

  • Be part of multiple research efforts, without leaving home

    Your community’s de-identified records can advance multiple treatment studies.

BENEFITS TO JOINING

What you’ll get along the way

We do the work to collect all your records, at no cost, in your secure account. Access doctors’ notes you’ve never seen.

Access your records

We do the work to collect all your records, at no cost, in your secure account. Access doctors’ notes you’ve never seen.

See how your rare disease journey compares to others with your condition, and what’s helping.

Learn from your community

See how your rare disease journey compares to others with your condition, and what’s helping.

We’ll send you exclusive updates on the studies you’re contributing to and how you’re driving forward research.

Track your impact

We’ll send you exclusive updates on the studies you’re contributing to and how you’re driving forward research.

Join now

Our work with alloimmunization & HDFN research

Hemolytic disease of the fetus and newborn (HDFN), also known as erythroblastosis fetalis, is a blood disorder that occurs when the blood types of a mother and fetus are incompatible. Women who are exposed to a blood type different from their own, usually from a blood transfusion or a pregnancy, can create antibodies to destroy the foreign red blood cells. If the woman becomes pregnant with a fetus who has an incompatible blood type, her antibodies can cross the placenta and destroy the fetus’ red blood cells. This may cause symptoms such as anemia, enlarged organs, or hydrops in the fetus. After birth, babies with HDFN may experience anemia, hyperbilirubinemia (excess bilirubin in the blood caused by red blood cells breaking down too rapidly), jaundice, neutropenia or thrombocytopenia after birth.

Some babies with HDFN have no symptoms, while other babies are severely affected and may die during the second or third trimester or after birth. However, with close monitoring and timely treatment, babies with HDFN have a high rate of survival.

The latest on our research: We are jumpstarting our Alloimmunization & HDFN program to accelerate research on the condition and welcome all parents and caregivers interested in participating and spreading the word to the Alloimmunization & HDFN community.

  • Jumpstart
  • Accelerate
  • Insights

The alloimmunization & HDFN program is in the jumpstart stage.

How it works

Sign up

1. Sign up

Create your private account and review our research consent (takes about 10 minutes)

We get to work

2. We get to work

We do all the behind-the-scenes work to retrieve and process your records

Impact research

3. Impact research

Power multiple research projects at once by contributing your de-identified data

Still have questions?

Check out our FAQs

Our values & principles.

1
Patients own their data

We believe that the only way to keep data accessible to the researchers who need it is by enabling patients to own and control their own data. Patients decide for themselves whether they want to privately and securely contribute to research, rather than having the decision made on their behalf.

2
We protect patient privacy

We abide by a strict research consent and privacy policy. We only share de-identified data with researchers, foundations, and therapeutic companies with patients’ consent. Protecting the privacy of patients and ensuring the security of their information is our highest priority.

3
Researchers gain access

We aim to make useful data accessible to all researchers who have legitimate research questions or research programs. For academic research, we offer access without charge. We take research ethics seriously, and we have policies in place to ensure that research is conducted with integrity.

4
Inclusiveness in the community

We don’t like to take sides—we give all members of the community the option to get involved. Success in rare disease research takes a village and we always welcome additional collaborators who can advance and benefit from the mission.

5
Driving forward therapeutic development

Our primary mission is to accelerate drug development, so we prioritize generating insights specifically relevant to therapeutic research. We invest deeply in quality, security, and compliance to make this a reality.